NCT00163085View on ClinicalTrials.gov

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2005

Study Completion Date

January 31, 2006

Conditions
Parkinson's Disease
Interventions
DRUG

NR2B NMDA Antagonist CP-101,606 (traxoprodil)

Trial Locations (1)

97239

Pfizer Investigational Site, Portland

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY